EGI
ALT icon

EAM Global Investors’s Altimmune ALT Stock Holding History

EAM Global Investors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-84,821
Closed -$1.08M – 178
2022
Q3 		$1.08M Sell
84,821
-41,174
-33% -$608K 0.29% 167
2022
Q2 		$1.47M Buy
+125,995
New +$777K 0.36% 138

Other funds holding ALT

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM Global Investors's ALT Position: Q4 2022 in Review

EAM Global Investors sold out of Altimmune (ALT) in Q4 2022, closing a stake of 84,821 shares — an estimated $1.08M sold.

EAM Global Investors first reported a position in ALT in Q2 2022 and held it in 2 quarters. The position peaked at $1.47M in Q2 2022. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • EAM Global Investors reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • EAM Global Investors sold 84,821 Altimmune shares in Q4 2022, an estimated $1.08M.
  • EAM Global Investors first reported a position in Altimmune in Q2 2022 and held it in 2 quarters.
  • EAM Global Investors's Altimmune position peaked at $1.47M in Q2 2022.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.